AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02103946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Muscle Plane block (SAM block)
Description: The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
Study NCT02103946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
Study NCT02375256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
Study NCT02375256 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical buffer solution in which AERAS-402 is formulated.
Study NCT02375256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG (1-8 x105 cfu ID)
Description: BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
Study NCT02375256 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG (1-8 x105 cfu ID)
Description: BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 500mg po bid/100mg po q8h for 7 days
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 500mg po bid/100mg po q8h for 14 days
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg po bid/200mg po q8h for 14 days
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg/600mg po twice daily for 14 days
Study NCT00801255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 1000mg/900mg po twice daily for 14 days
Study NCT06237764 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention.
Study NCT01455844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre (TM)
Description: CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
Study NCT01455844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
Study NCT02746536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow chest compression
Description: During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air.
Study NCT02746536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No slow chest compression
Description: The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air.
Study NCT01455844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre (TM)
Description: CaPre™ 2.0g daily for 12 weeks
Study NCT01811563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer
Study NCT01811563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker
Study NCT04433793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Description: One yoga session will last one hour. It consists of physical exercises (asanas), conscious breathing (Pranayama) and deep relaxation (Savasana). The subsequent body exercises are structured from lying to sitting to standing. The following sequence of exercises will be repeated in each yoga unit: 1) Relaxation: conscious breathing, body scan, mindfulness 2) Vein pump 3) Pelvis and back rotation (adapted variation of the nakrasana) 4) Pelvis opening (adapted variation of the supta baddha konasana) 5) Shoulder bridge (setu bandha sarvangasana) 6) Forward folds (Paschimottanasana and variations with Pranayama) 7) Backbend: intense east stretch (Purvottasana) 8) Diagonal static yoga cat (Majariasana 1 and resting pose) 9) Standing exercise 10) Upward Salute(Urdhva Hastasana) 11) Warrior 1 (Virabhadrasana 1) 12) Warrior 3 (Virabhadrasana 3) 13) Tree (Vrkasana variation) 14) Relaxation (Savasana).
Study NCT00329719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT00329719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00329719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT04525183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care (EOC)
Description: Educational materials
Study NCT00329719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT04525183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REVITALIZE ACT Intervention
Description: Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
Study NCT05254860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPS Ventral Rectopexy
Description: Continuous Locked Suture vs Traditional 6-points suture for Laparoscopic Ventral Rectopexy to verify if the operative time of a standard laparoscopic ventral rectopexy for the treatment of severe rectal prolapse could be further reduced using continuous locked suture vs traditional 6-points suture for mesh fixation
Study NCT04088292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase 20 Mg Powder for Solution for Injection Vial
Description: Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
Study NCT04088292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assisted Thrombolysis
Description: Ultrasound assisted thrombolysis (USAT)
Study NCT03776240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD201
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Study NCT03776240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Herceptin
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Study NCT03776240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Herceptin
Description: Single-dose 6mg/kg body weight by 90 minute intravenous infusion
Study NCT04082442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab.
Study NCT04082442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Matching placebo.
Study NCT02893436 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery with tracheal intubation curarisation
Study NCT04082689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Infant Toilet Training
Description: The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty.
Study NCT03368521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Back pain screening test
Description: The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
Study NCT00558207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: 120 mg capsule administered twice daily for 240 mg total daily dose
Study NCT00558207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
Study NCT03172559 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
Study NCT01029873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
Study NCT01029873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)
Study NCT02991859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) Dry Powder Inhaler
Description: Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
Study NCT03706898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir, film-coated tablets, 50mg
Study NCT03706898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir, film-coated tablets, 400mg
Study NCT03706898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir, film-coated tablets, 60mg
Study NCT01795820 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: loading with Ticagrelor
Description: Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
Study NCT01795820 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: no loading with Ticagrelor
Description: Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor.
Study NCT04314310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam
Description: nonsteroidal anti-inflammatory drug (NSAID)
Study NCT04314310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: equal volume of normal saline
Study NCT03119207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naptime Protocol
Description: Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
Study NCT02991859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) Dry Powder Inhaler
Description: Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
Study NCT02991859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) Turbuhaler
Description: Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
Study NCT03425227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRED EXERGAME
Description: biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
Study NCT04088604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection )
Description: Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
Study NCT04088604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
Description: Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
Study NCT04088604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection（CAMPTO®）
Description: Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
Study NCT00560378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Description: Topical
Study NCT05342532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1 g
Study NCT05342532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40 mg. Patients were asked to take omeprazole one hour prior to food intake, while antibiotics were taken after meals.
Study NCT05342532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: 500 mg twice daily
Study NCT04150406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flexofytol
Description: Curcuma extract
Study NCT04150406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02948218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
Study NCT02063971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)
Study NCT04255927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coated Vicryl plus
Description: Vicryl plus (Coated Polyglactin 910 with Triclosan)
Study NCT04255927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coated vicryl
Description: Vicryl (Coated Polyglactin 910 without Triclosan)
Study NCT00558571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 low dose
Study NCT00558571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to BI 10773
Study NCT00558571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 medium dose
Study NCT00558571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 high dose
Study NCT02325791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg
Description: Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
Study NCT02325791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to Suptavumab
Description: Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
Study NCT02325791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg- 1 Dose
Description: Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
Study NCT02325791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suptavumab 30 mg/kg - 2 Doses
Description: Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
Study NCT03862040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Administered intravenously, at a dosage determined based on renal function.
Study NCT03862040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Antibiotic
Description: Standard of care antibiotic treatment for pneumonia
Study NCT03665831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H1-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
Study NCT04094077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX
Description: 2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
Study NCT03596632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: 200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib
Study NCT01028378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
Study NCT01763242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMAN
Description: See details on ESA Synchronization and Dosing in Detailed Description Above
Study NCT00527670 — intervention group
Intervention type: PROCEDURE
Intervention: Normal Controls
Description: The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
Study NCT00527670 — intervention group
Intervention type: PROCEDURE
Intervention: Recurrent Hernia
Description: This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
Study NCT01298193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Efficacy phase (second cycle)
Study NCT01216007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
Study NCT01216007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
Study NCT05811650 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral Health Counseling and promotion
Description: The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
Study NCT05811650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health Counseling and promotion
Description: The intervention was cluster randomized control trial in design. We select six schools for the intervention group and six schools for the control group. Follow-up of the intervention was done after six months of baseline. Impact of the intervention was assessed among the same participants who enrolled in the baseline. The interventions were done in every three months.
Study NCT02448836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Description: Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).